Nebivolol Stada (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which reduces heart rate and contractility, lowering blood pressure. Additionally, it enhances nitric oxide release from the endothelium, causing vasodilation that further contributes to its antihypertensive effect.

The exact dose of Nebivolol Stada is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Dosage adjustments are made according to clinical guidelines and patient monitoring.

Nebivolol Stada is generally not recommended during pregnancy or lactation unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol differs from many traditional beta blockers by also promoting nitric‑oxide‑mediated vasodilation, which can improve endothelial function and cause fewer metabolic side effects. This dual mechanism may offer advantages in patients who need both blood‑pressure control and better vascular health.

Nebivolol Stada tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nebivolol Stada is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe bradycardia, hypotension, worsening heart failure, bronchospasm in patients with asthma or COPD, and rare allergic reactions. Patients should be monitored for these events, especially during treatment initiation or dose changes.

Nebivolol Stada is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with cardiogenic shock. Caution is also advised for patients with severe liver impairment.